Pengaruh Terapi Dapagliflozin terhadap Rehospitalisasi Pasien Gagal Jantung di RSUD Welas Asih
DOI:
https://doi.org/10.29313/bcsp.v6i2.24811Keywords:
Gagal Jantung, Rehospitalisasi, DapagliflozinAbstract
Abstract. Heart failure is a chronic clinical syndrome with a high rehospitalization rate and contributes significantly to increased morbidity and mortality. Dapagliflozin is recommended as one of the therapeutic options for heart failure because it has been shown to improve clinical outcomes. This study aimed to evaluate rehospitalization rates associated with dapagliflozin-containing therapy regimens and to assess physical and laboratory parameters in patients with heart failure at RSUD Welas Asih, West Java Province, during the 2024–2025 period. This retrospective observational study used medical record data from patients who met the inclusion and exclusion criteria. The evaluated parameters included Left Ventricular Ejection Fraction (LVEF), blood pressure, heart rate, peripheral edema, troponin, and hemoglobin. Of the 144 patients, 35 experienced rehospitalization, whereas 109 did not. The results showed that dapagliflozin-containing therapy regimens were associated with lower rehospitalization rates. Therefore, dapagliflozin-containing therapy has the potential to improve clinical outcomes and reduce the risk of rehospitalization in patients with heart failure.
Abstrak. Gagal jantung merupakan sindrom klinis kronis dengan angka rehospitalisasi yang tinggi serta berkontribusi terhadap peningkatan morbiditas dan mortalitas. Dapagliflozin direkomendasikan sebagai salah satu terapi gagal jantung karena dapat memperbaiki luaran klinis pasien. Penelitian ini bertujuan untuk mengetahui perbedaan angka rehospitalisasi berdasarkan regimen terapi yang mengandung dapagliflozin serta mengevaluasi parameter fisik dan laboratorium pada pasien gagal jantung di RSUD Welas Asih Provinsi Jawa Barat periode 2024–2025. Penelitian ini menggunakan desain observasional retrospektif dengan data rekam medis pasien yang memenuhi kriteria inklusi dan eksklusi. Parameter yang dievaluasi meliputi Left Ventricular Ejection Fraction (LVEF), tekanan darah, nadi, edema perifer, troponin, dan hemoglobin. Dari 144 pasien, sebanyak 35 pasien mengalami rehospitalisasi dan 109 pasien tidak mengalami rehospitalisasi. Hasil penelitian menunjukkan bahwa regimen terapi yang mengandung dapagliflozin berhubungan dengan angka rehospitalisasi yang lebih rendah. Dengan demikian, pemberian terapi yang mengandung dapagliflozin berpotensi memberikan luaran klinis yang lebih baik dan menurunkan risiko rehospitalisasi pada pasien gagal jantung.
References
Besmaya, B. M. &, & Laksono, S. (2023). Mekanisme Penghambat Sodium-Glukosa Transport Protein-2 (SGLT2-i) pada Penyakit Kardiovaskular: Sebuah Tinjauan. MPI (Media Pharmaceutica Indonesiana), 5(1):71–85., 5(1).
Bozkurt, B., Coats, A. J., Tsutsui, H., Abdelhamid, M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., Drazner, M. H., Felker, G. M., Filippatos, G., Fonarow, G. C., Fiuzat, M., Gomez-Mesa, J. E., Heidenreich, P., Imamura, T., Januzzi, J., … Zieroth, S. (2021). Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure, 27(4), 387–413. https://doi.org/10.1016/j.cardfail.2021.01.022
Donsu, R. A., Rampengan, S. H., & Polii, N. (2020). Karakteristik Pasien Gagal Jantung Akut di RSUP Prof Dr. R. D. Kandou Periode Januari-Desember 2018. Medical Scope Journal, 1(2). https://doi.org/10.35790/msj.1.2.2020.27463
Gronda, E., Dusi, V., D’elia, E., Iacoviello, M., Benvenuto, E., & Vanoli, E. (2022). Sympathetic activation in heart failure. European Heart Journal, Supplement, 24(Se), E4–E11. https://doi.org/10.1093/eurheartjsupp/suac030
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
Kemenkes BKPK. (2023). Survei Kesehatan Indonesia (SKI) dalam Angka. Kementrian Kesehatan Badan Kebijakan Pembangunan Kesehatan.
McDonagh, T. A., Metra, M., Adamo, M., Baumbach, A., Böhm, M., Burri, H., Čelutkiene, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gardner, R. S., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., … Koskinas, K. C. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. In European Heart Journal (Vol. 42, Number 36, pp. 3599–3726). Oxford University Press. https://doi.org/10.1093/eurheartj/ehab368
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., & Solomon, S. D. (2019). The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure, 21(11), 1402–1411. https://doi.org/10.1002/ejhf.1548
Mentzer, G., & Hsich, E. M. (2019). Heart Failure with Reduced Ejection Fraction in Women: Epidemiology, Outcomes, and Treatment. In Heart Failure Clinics (Vol. 15, Number 1, pp. 19–27). Elsevier Inc. https://doi.org/10.1016/j.hfc.2018.08.003
Mesquita, E. T., Jorge, A. J. L., Rabelo, L. M., & Souza Jr., C. V. (2016). Understanding Hospitalization in Patients with Heart Failure. International Journal of Cardiovascular Sciences. https://doi.org/10.5935/2359-4802.20160060
Naderi, N., Chenaghlou, M., Mirtajaddini, M., Norouzi, Z., Mohammadi, N., Amin, A., Taghavi, S., Pasha, H., & Golpira, R. (2022). Predictors of readmission in hospitalized heart failure patients. Journal of Cardiovascular and Thoracic Research, 14(1), 11–17. https://doi.org/10.34172/JCVTR.2022.08
Patoulias, D., Fragakis, N., & Rizzo, M. (2022). The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest. In Life (Vol. 12, Number 12). MDPI. https://doi.org/10.3390/life12122062
PERKI. (2023). Pedoman Tatalaksana Gagal Jantung (3 ed). Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
Powell, J. T., & Sweeting, M. J. (2015). Retrospective studies. In European Journal of Vascular and Endovascular Surgery (Vol. 50, Number 5, p. 675). W.B. Saunders Ltd. https://doi.org/10.1016/j.ejvs.2015.07.005
Prihatiningsih, D., & Sudyasih, T. (2018). Perawatan Diri Pada Pasien Gagal Jantung. Jurnal Pendidikan Keperawatan Indonesia, 4(2). https://doi.org/10.17509/jpki.v4i2.13443
Purna singh, A., Vadakedath, S., & Kandi, V. (2023). Clinical Research: A Review of Study Designs, Hypotheses, Errors, Sampling Types, Ethics, and Informed Consent. Cureus. https://doi.org/10.7759/cureus.33374
Saisho, Y. (2020). SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes? In Diseases (Vol. 8, Number 2). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/diseases8020014
Shao, S. C., Chang, K. C., Lin, S. J., Chang, S. H., Hung, M. J., Chan, Y. Y., & Lai, E. C. C. (2021). Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Cardiovascular Diabetology, 20(1). https://doi.org/10.1186/s12933-021-01406-3
Soerarso, R., Hasanah, D. Y., Yonas, E., Tawari, F. M. Y., Raharjo, S. B., Siswanto, B. B., Cramer, M. J., van der Harst, P., & Oerlemans, M. I. F. J. (2024). Effect of Post-Loop Diuretic Urinary Sodium Level on Length of Stay and Rehospitalization in Acutely Decompensated Heart Failure Patients. Cardiology Research, 15(5), 350–357. https://doi.org/10.14740/cr1696
Wang, R. B., Yick, M. C. T., Thomas, M., Woldman, S., Davies, C., Badiani, S., Das, D., Wright, P., Antoniou, S., Primus, C., Papalia, F., Gallagher, A. &, & Velmurugan, S. (2024). Rehospitalisation rates of heart failure patients treated with SGLT2 inhibitors as an inpatient versus post-discharge. British Journal of Cardiology, (31), 101–105. https://doi.org/10.5837/bjc.2024.032
